Pharmaceuticals, Biotechnology and Life Sciences
The fourth quarter of 2016, global net sales of Praluent were $41 million, compared to $7 million in the fourth quarter of 2015.
Sanofi and Regeneron will continue marketing, selling and manufacturing Praluent in the United States (U.S.) during their appeal on Amgen’s patent claims.
Amgen’s new injectable cholesterol drug Repatha has been turned down for use on Britain’s state health service, underscoring a worldwide debate about the value of such pricey medicines.